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1. Introduction 
Enkorten is a new potential drug for the treatment of rheumatoid arthritis, with an 
immunomodulatory and anti-inflammatory effect. It is a combination of two peptide 
components of endogenous origin: methionine-enkephalin of 5 mg and tridecactide of 1 mg 
(Picture 1 and 2). According to the chemical structures, these components correspond to 
amino acid sequences of the neuropeptide precursor proopiomelanocortin.  
 
Generic name:  tridecactide 
Chemical name:  (des-acetyl)--MSH-(de-amid) - -MSH 
Gross formula:  C75H106N20O19S 
Molecular weight: 1623.85 
Amino acid sequence: H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-OH  
Picture 1. Chemical characteristics of tridecactide 
Generic name:  met-enkephalin 1-5 adrenorphin  
Gross formula:  C27H35N5O7S 
Molecular weight: 573.67 
Amino acid sequence: H-Tyr-Gly-Gly-Phe-Met-OH 
Picture 2. Chemical characteristics of met-enkephalin 
The holder of effects of the tested combination is alpha 1-13 corticotrophin–tridecactide 
(ACTH 1-13), composed of 13 amino acids, identical to the amino acid sequence of the 
alpha-melanostimulating hormone (-MSH), but without the acetyl and amide ending. 
Some studies suggest that -MSH is synthesized in the pituitary, other parts of the CNS, the 
placenta, and some endocrine organs – especially the adrenal, the skin and the 
gastrointestinal tract (Star et al, 1995; Catania et al, 2000). The presence of this neuropeptide 
in the mucous membrane of the gastrointestinal tract and keratinocytes of the skin suggests 
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that it is a component of natural immunity (Catania et al, 2000a). The supposed connection 
between alpha-MSH and immune processes is confirmed by the clinical data on changes of 
its plasma level under certain pathological conditions (Lipton and Catania, 1997; Lipton et 
al, 2000). An increased concentration of -MSH has been recorded in patients with an acute 
myocardial infarction who received thrombolytic therapy, probably as an endogenous anti-
inflammatory response. This peptide has been identified in the synovial fluid of patients 
with rheumatoid arthritis (Star et al, 1995) and it is believed that the inflammation and joint 
destruction in this disease occur due to imbalances of production of proinflammatory and 
anti-inflammatory cytokines such as -MSH. A higher concentration of -MSH has been 
found in patients suffering from arthropathy accompanied by heavy inflammation (Lipton et 
al, 2000). Since -MSH is a natural modulator peptide, its concentration is subject to intensive 
control to avoid excessive inhibition of the immune response. It is assumed that the increased 
concentration of peptides leads to downregulation of receptors in cells, which could explain 
the biphasic curve of the anti-inflammatory effects -MSH (Catania et al, 2000).  
The other component contained in the drug is met-enkephalin, which belongs to a group of 
endogenous opioid peptides, widely distributed in the CNS. All opioid peptides contain one 
or more copies of the simplest opioid peptides: methionine-enkefalin (tyrosine-glycine-
glycine-phenylalanine-methionine) and leucine-enkephalin (tyrosine-glycine-glycine-
phenylalanine-leucine) (Janković, 1991). They participate in, and modulate 
neurotransmission. Opioid peptides also act as growth factors that control proliferation and 
differentiation of cells and may participate in the process of wound healing, tissue 
regeneration and immune response. Enkephalins show antidepressant, antianxiety and 
anticonvulsive effects. They are produced in the adrenal and the hypothalamus. Met-
enkephalin belongs to a group of enkephalins that are involved in transmitting signals in the 
nervous system, intestines, endocrine glands, bronchial tree, lymphatic and other tissues 
(Štambuk et al, 1996). The highest concentrations are present in the core of adrenal, 
hypothalamus, autonomic ganglia and the gastrointestinal tract (Janković, 1991).  
Met-enkephalin as an inhibitory peptide modulates the proliferation and migration of cells, 
as well as the organization of tissues during development, homeostatic cell renewal, wound 
healing, angiogenesis, and in malignant neoplasms (Zagon et al, 2000). Physiologically, 
enkephalins have a signalling function in the nervous system, intestine, endocrine glands, 
bronchial tree, cardiovascular system, lymphatic and other tissues, and participate in the 
regulation of haematopoiesis (Štambuk et al, 1996). It is assumed that they participate in 
maintaining homeostasis of the organism exposed to stress (Mulabegović et Rakanović-
Todić, 2008).  
2. The place and importance of -MSH and met-enkephalin in 
immunomodulation  
Immunomodulatory effects of a combination of -MSH and met-enkephalin involve several 
mechanisms that support the modern trend in the development of new anti-inflammatory 
drugs. The method of selective immunomodulation using peptides has only recently been 
used in immune-mediated diseases and malignant neoplasm. Immunomodulation with 
antigens and peptides is directed towards achieving a satisfactory long-term remission 
without the occurrence of toxic side effects typical for immunosuppressive drugs. It is based 
on two approaches: the first approach is to block the initial activation of antigen recognition 
of autoreactive T cells, while the second is based on downregulation of specific antigenic 
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inflammatory response of T cells through the activation of regulatory physiological 
mechanisms (Štambuk et al, 1997). 
Until recently it was thought that the immune/inflammatory reaction develops exclusively 
in the periphery. Today it is known that the nervous, endocrine and immune systems are 
interconnected, and that they communicate by signals that are transmitted through 
neuropeptides. In this way, central neurogenic influences can either enhance or modulate 
the peripheral response, so by analogy the treatment of inflammatory reactions could be 
improved by the influence of the proinflammatory signals in the central nervous system. 
Thus, Catania et al. (1999) suggest that one of these strategies could be based on the action of 
-MSH.  
In the past several years, particular attention has been given to the anti-inflammatory effects 
of this peptide, as a result of the introduction of -MSH and related peptides in clinical 
practice for the treatment of inflammatory diseases (Getting, 2006). Undoubtedly, -MSH, 
administered systemically or locally, expresses strong anti-inflammatory effects. Anti-
inflammatory effects of this peptide are mediated by direct effects on cells of the immune 
system, as well as by indirect effects that are achieved by changing the function of non-
resident immune cells of peripheral tissues (Luger and Brzoska, 2007).  
Three basic mechanisms of -MSH anti-inflammatory action can be distinguished: direct 
effects through melanocortin receptors on cells in the periphery (monocytes/macrophages 
and neutrophils); effects on glial cells; and descendent anti-inflammatory effects through 
melanocortin receptors on neurons (Lipton et al, 2000). These mechanisms of action 
correspond to the concept of neuroimmunomodulation in which nerves, endocrine and 
immune systems are independent networks that mutually communicate through soluble 
mediators such as cytokines and neuropeptides. 
Multiple anti-inflammatory effects that -MSH has have been identified in various in vitro 
systems of cell cultures. Studies of anti-inflammatory effects of -MSH on cellular level were 
primarily concentrated on the issue whether and to what degree -MSH suppresses the 
production of pro-inflammatory cytokines. In this respect, several studies have shown that 
treatment with -MSH results in significant downregulation of pro-inflammatory cytokines 
such as IL-1, IL-2, IL-4, IL-6, IL-13 and TNF-, as well as chemokines such as IL8, Gro and 
interferon  (IFN) (Brzoska et al, 2008). Furthermore, chemotaxis induced by IL8 in the cells 
of human neutrophils and monocytes has been suppressed under the influence of -MSH 
(Manna et al, 2006), which indicates that the function of these types of phagocytic cells 
during the inflammatory response is blocked by the peptide via multiple effector pathways.  
Contrary to the inhibitory effects of -MSH on the production and activity of pro-
inflammatory mediators, it has been found that -MSH induces IL-10, a cytokine with a 
potent anti-inflammatory activity. Specifically, in monocytes of human peripheral blood and 
cultivated human monocytes, -MSH increases the production and expression of IL-10 
(Bhardway et al, 1996). Since IL-10 reduces the production of pro-inflammatory cytokines in 
macrophages, its upregulation could result in anti-inflammatory influences.  
Studies on different cell types of human skin, including pigment cells, fibroblastic cells and 
dermal microvascular endothelial cells, as well as rat mast cells, showed that -MSH is able 
to suppress the expression of several intracellular adhesion molecules (interstitial adhesion 
molecule-1 - ICAM-1 and P-selectin) induced by proinflammatory stimuli such as IFN-, 
LPS and TNF-Böhm et al, 2005; Hill et al, 2006; Sarkar et al, 2003). Finally, the inhibition 
of adhesion and transmigration of inflammatory cells may contribute to the anti-
www.intechopen.com
 
Rheumatoid Arthritis – Treatment 
 
158 
inflammatory potential of -MSH (Böhm et al, 2005; Scholzen et al, 2003). Moreover, it was 
found that -MSH inhibits the maturation of dendritic cells and downregulates the 
expression of co-stimulatory molecules on antigen-presenting dendritic cells, such as CD86, 
CD40 and CD54 (Luger, 2003; Capsoni et al, 2007).  
One of the mechanisms that could explain the anti-inflammatory action of -MSH is the 
suppression of pro-inflammatory non-cytokine mediators under the influence of this 
peptide. The inhibitory effect of -MSH on the synthesis of prostaglandin has long been 
known. This peptide suppressed the synthesis of PGE in the fibroblast of foetal human lung 
stimulated with IL-1 (Cannon et al, 1986). The effect of -MSH on the synthesis of PGE is 
cell specific. Confirmation of this is the fact that under the influence of -MSH, 
TNFinduced production of PGE2 in FM55 melanoma cells was blocked, but not in HaCaT 
keratinocytes (Nicolaou et al, 2004).  
The induction of the inducible form of the enzyme nitric oxide synthase (iNOS) and the 
release of gaseous vasodilator nitric oxide (NO) after the stimulation of cells with various 
pro-inflammatory stressors, i.e. LPS, -IFN and -amiloid, can also be suppressed under the 
influence of -MSH (Tsatmali et al, 2000; Gupta et al, 2000; Caruso et al, 2007; Jung et al, 
2007). The increased expression of NOS, and nitration of cellular proteins in the blood and 
synovial fluid of a patient with rheumatoid arthritis has been registered. 
Immunomodulatory effects of -MSH realized through NO may be more important in 
rodent than in human cells, since human monocytes are known to contain only marginal 
amounts of this gaseous mediator. 
Recent studies have shown that -MSH inhibits the production of superoxide radicals in 
neutrophils of rats treated with LPS or forbolester (Oktar et al, 2004). Similarly, -MSH 
reduced the amount of oxidative burst in HL-60 cells, a cell line of human monocytes 
(Manna et al, 2006). Although there is no evidence to suggest that -MSH itself is a real 
radical quencher, these findings are in accordance with other reports that indicate an effect 
of this peptide on cellular redox balance and the process of apoptosis as well.  
Regarding the release of histamine by mast cells, various effects of -MSH have been 
described which are likely related to species-specific differences, the type of mast cells and 
experimental conditions. In mast cells obtained from rat bone marrow, -MSH inhibited the 
antigen-induced histamine release together with the suppression of other pro-inflammatory 
cytokines (Adachi et al, 1999).   
There are only a few studies that have researched the effect of -MSH on the function of 
lymphocytes, probably due to the fact that the total expression of melanocortin receptors in 
several lymphocyte lines is low or undetectable (Andersen et al, 2005). It is known that -
MSH induces subpopulation of regulatory T lymphocytes. Regulatory T cells induced with 
-MSH are characterized by the expression of CD25, CD4 and CTLA4 and production of 
increased levels of TGF-2 (Namba et al, 2002). In the human system, -MSH also expresses 
modulator effects on T cells. Cooper and associates (2005) found that -MSH suppresses the 
proliferation of human T lymphocytes stimulated by streptokinase/streptodornase. This 
inhibitory effect of -MSH was independent of the genotype MC-1R, which is highly 
polymorphous with more than 35 genetic variations. 
Numerous effects of -MSH on the production of inflammation mediators were a mystery 
to researchers until it was found that this peptide inhibits the activation of the nuclear factor 
kappa B (NF-B) (Mandrika et al, 2001; Hassoun et al, 2002). This essential nuclear factor 
induces the transcription of many molecules involved in the inflammatory process, and 
www.intechopen.com
 
Enkorten – A Potential Drug for the Treatment of Rheumatoid Arthritis 
 
159 
therefore its inhibition results in the alteration of mediators’ production and cell functions. 
NF-B participates in the regulation of hundreds of genes, including those for cytokines, 
chemokines, factors for haematopoietic system growth, antiapoptotic factors and the 
inducible synthesis of nitric oxide (iNOS). Therefore, the discovery that -MSH inhibits 
activation of NF-B provides an explanation for numerous effects of this peptide on the 
production of mediators.  
Anti-inflammatory effects of -MSH in vitro have  also been identified  in vivo in various 
animal models. These have confirmed a number of effects of melanocortin on the production 
of mediators of inflammation. The anti-inflammatory activity of -MSH in animal models of 
arthritis is of special interest. Repeated intraperitoneal application of the peptide twice daily 
resulted in a significant reduction of clinical and histological signs of adjuvant-induced 
experimental arthritis as compared to control animals. The efficiency of -MSH was similar 
to that of prednisolone, but -MSH did not cause significant weight loss (Ceriani et al, 1994). 
Some data indicate that the melanocortin receptor MC-3R may be a relevant target for the 
treatment of arthritis. 
During the early phase of inflammation (associated with tissue destruction and activation of 
nociceptors) mediators of inflammation, including cytokines, chemokines, bradykinin, 
prostaglandins act as mediators of hyperalgesia. At the same time, the expression of 
peripheral opioid receptors on sensory nerve endings increases during inflammation 
(Rittner et al, 2003), which leads to the release of pain mediators, such as opioid peptides, 
somatostatin, endocannabinoids and certain cytokines. Endogenous opioid peptides, leucine 
and met-enkephalin act presynaptically when they inhibit the release of neurotransmitters, 
and postsynpatically when they suppress the activity of the postsynaptic neurone, and block 
the transmission of ascending pain signals (Rang, 2005).  
In addition to the central nervous system, met-enkephalin influences the function of the 
immune system (Vujić-Redžić, 2000). It is released from polymorph nuclear cells during 
inflammation and periods of stress (Rittner et al, 2006). In inflammation, there is a migration 
of leukocytes that contain opioid peptides, and also the upregulation of opioid receptors of 
afferent fibres. This is supported by the fact that IL-1 is a specific inductor of expression of 
kappa opioid receptors (Puehler et al, 2006). Interleukin-1, together with TNF-ǂ, is the main 
proinflammatory cytokine released from macrophages and many other cells, which initiates 
the release of other cytokines (Rajora et al, 1997).  
In in vitro studies, it was found that T lymphocytes have opioid receptors on their surface 
(Wybran et al, 1985), and according to Plotnikoff and associates (1991), the effects of 
enkephalin are precisely related to the immune response mediated by T cells. In addition, 
the corticotropin-releasing hormone, similarly to the pituitary gland, appears dose-
dependent locally, through delta opioid receptors, and leads to the release of opioid 
peptides from leukocytes and the induction of endogenous analgesia (Menzebach et al, 2003; 
Cabot et al, 2001). 
Met-enkephalin manifests central, bimodal and dose dependent immunomodulatory effects. 
A bi-phasic effect was registered in in vivo studies on rats. High doses have suppressed, 
while low doses potentiated a humoral immune response (Janković and Marić, 1994). The 
studies in vivo of the immunomodulatory effect of met-enkephaline on rats showed a 
suppressive action of high doses of met-enkaphalin on inflammatory reactions, such as the 
systemic anaphylactic shock (Janković and Marić, 1987), Arthus phenomenon and 
postponed skin reactions to protein antigens (Marić and Janković, 1987), the rejection of 
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allograph (Janković, 1991), arthritis (Janković, 1991) and the experimentally induced allergic 
encephalomyelitis (Veljić et al, 1991).  
In studies conducted at the Charité University in Berlin on the effect of intraarticular 
application of opioids in comparison to the intraarticular application of glucocorticoids in 
patients with the chronic inflammatory arthritis accompanied by pain and functional 
impairment, according to the established hypothesis, local application of opioids led to a 
significant reduction of pain and inflammation, which can be explained by the activation of 
peripheral opioid receptors (that have been identified on peripheral sensory nerve endings), 
and subsequent decreases in neural excitability, transmission of nociceptive impulses, and 
reduced release of proinflammatory neurotransmitters (Stein et al, 2001; Mousa et al, 2001).  
In summary, preclinical studies indicate that the activation of melanocortin receptors could 
be a new strategy to control inflammation (Catania et al, 2004). Similarly to any new 
therapeutic approaches, this strategy may have both advantages and disadvantages in 
comparison to the currently available medications. The main advantage of melanocortin in 
the treatment of inflammation is that its anti-inflammatory activity is not restricted to a 
specific mediator or a chemical process.  In fact, as a consequence of reduced activation of 
the nuclear factor NF-B, the collective reduction of all important molecules involved in the 
inflammatory process is evident.  
Another positive aspect is the fact that the treatment with melanocortin peptides never 
reverses the inflammatory response, but modulates it. It is well known that the 
inflammatory response is a crucial reaction of the host that contributes to the elimination of 
pathogens and harmful molecules. Cytokines, which are a major component of the 
inflammatory process, also have a significant function in regulating the recovery of tissues, 
haematopoiesis and immune responses. Any agent that completely inhibits their production 
or action would have a detrimental impact on the host defence mechanism. Melanocortin 
peptides modulate the increased production of cytokines during infection or inflammation, 
but do not prevent their release. Besides, they do not affect the production of mediators of 
inflammation when being on complete rest. So, for example, alpha-1-13 corticotrophin 
modulates the febrile response caused by pyrogens, while on the other side, it does not 
cause any changes to the non-febrile temperature of the body. 
The main advantage of the melanocortin in relation to the currently used anti-inflammatory 
drugs, particularly corticosteroids, is that neuropeptides do not reduce the microbicidal 
activity of neutrophils, but  instead increase it. This feature could be very important in the 
treatment of inflammation in immunecompromised persons.  
The lack of selectivity could be a potential problem when it comes to the use of natural 
melanocortin peptides. Today, it is clear that the melanocortins affect many body functions, 
including the regulation of food consumption, sexual behaviour and pigmentation. Systemic 
injection of non-selective peptide could, therefore, cause adverse effects by stimulating all 
subtypes of receptors. However, the design and synthesis of new melanocortin analogues 
with a selective affinity for specific receptors could greatly facilitate the achievement of 
target effects. Knowledge of amino acid substitution that reduces binding to all receptors 
can also help prevent unwanted receptor activation. (Catania et al, 2004). Another potential 
problem lies in the rapid splitting, or degradation of peptide molecules in the circulation 
and other body fluids, and natural melanocortins are no exception.  
The relatively short half-life could be a problem if it is necessary to maintain the 
concentration in the blood. On the other hand, the fact that the peptides are not accumulated 
www.intechopen.com
 
Enkorten – A Potential Drug for the Treatment of Rheumatoid Arthritis 
 
161 
in the body reduces the likelihood of toxicity and tolerance, and allows for better control of 
the pharmacological effects (Catania et al, 2004).    
3. Preclinical toxicological studies 
Enkorten toxicity testing was conducted according to the Instructions and Rules of Good 
Laboratory Practice (GLP) and Harmonized Tripartite Guideline issued in 1998.  
Objectives of preclinical toxicological studies were to determine the degree of toxicity of 
the investigated substance; to identify the target organs of toxicity and to determine the 
reversibility of the toxic effects; to detect the toxic effects that may help in the 
identification of the parameters for subsequent clinical trials and to determine the 
maximum tolerated dose. 
Preclinical toxicological studies were carried out in rats and rabbits. The experimental 
animals were Wistar albino rats bred in the breeding quarters in Harlan, Italy, and the rabbit 
strain was HY plus giant PS 19 gene, from France. Environmental conditions for animals in 
the vivarium were maintained constant with daily temperature and humidity monitoring. 
Semisynthetic food for laboratory animals ad libitum and the tap water that meets the 
Sarajevo city water-supply criteria for drinking water were used during study. Animals 
were randomly divided in groups according to dose levels. Three dose levels were 
determined using the method of multiplication of the anticipated maximum human 
therapeutic dose of 10 mg of met-enkephalin (substance a) and 2 mg of alpha-MSH 
(substance b): the dose equivalent to the anticipated human therapeutic dose (0.071 mg /kg 
a + 0.014 mg/kg b); 5 times higher dose (0.355 mg/kg a + 0.07 mg/kg b); 10 times higher 
dose (0.71 mg/kg a + 0.14 mg/kg b). Enkorten was applied as a constant volume dose of 
0.0005 ml/g according to the following dosage regime: during the first month - three times a 
week; during the second month - twice a week, and during the third month - once a week. 
The control group was treated by 0.9% of physiological NaCl solution. 
Treatment was followed by a 10-day observation period. The appearance of toxic signs was 
monitored on a daily basis. Weighing of individual animals was performed before dosing, 
once a week, and before the animals were sacrificed. Daily food and water consumption per 
cage, as well as the stool mass were recorded on a weekly basis.  
In subchronic and chronic studies, haematological and biochemical analyses were 
performed of the fasting blood samples taken from 12 animals from each of the 
experimental groups and from 24 animals from the control group, before the animals were 
sacrificed. The following haematological analyses were performed: hematocrit, haemoglobin 
concentration, red blood cell count, red blood cell morphology, total and differential white 
blood cell count, platelets. The following biochemical analyses were performed: Calcium 
(Ca+2), Potassium (K+), Sodium (Na+), Chloride (Cl -), Phosphorus (PO24-), glucose, Aspartal 
aspartate aminotransferase (AST) , Alanine aminotransferase (ALT), alkaline phosphatase 
(AP), Gamma-glutamyl transpeptidase (GGT), blood urea nitrogen (BUN), total proteins, 
albumin, globulin, total bilirubin, creatinine, lipids, and cholinesterase. 
Necropsy was performed only on the sacrificed animals (no lethality observed). Upon 
completion of the experiment, animals were sacrificed and both external and internal 
examinations of the sacrificed animals were performed. The following organs: brain, heart, 
lungs, liver, spleen, thymus, kidneys and adrenal glands, as well as samples of other 
macroscopically changed tissues were subjected to histopathological analysis.  
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Collected data were statistically analyzed using the Microsoft® Excel 2002 and SigmaStat 
programs for statistical analysis.  
3.1 Acute toxicity study 
The acute toxicity study was performed as the initial step of the prospective drug 
toxicological evaluation. Acute toxicity provides the important safety parameters for the 
prospective human overdose scenario and its expected clinical presentation. Traditionally, 
international authorities and governmental agencies had adopted the mean lethal dose as 
the sole measurement of acute toxicity. Testing of the rationally high doses, without 
detected lethality, is also acceptable and complies with the Limit Test concept (ICH, 2009; 
EMA, 2010).  
Acute toxicity was assessed on Wistar albino rats. The study was performed as the single 
dose testing following intravenous (i.v.), subcutaneous (s.c.) and intraperitoneal (i.p.) 
application, in accordance with the Limit Test methodology. The administered 
multiplications were: via i.v. route 50, 100 and 200 times; via s.c. route 100, 250 and 500 
times; and via i.p. route 100, 250, 500 times plus 1000 times in and additional group of males. 
Neither lethality, nor significant macroscopic and microscopic changes were observed at the 
necropsy following planned sacrificing. The necropsy and histopathological evaluation 
revealed no significant changes. No statistically significant differences in post-mortem organ 
weights were noted. 
The most prominent clinical signs were noted on day 1 of the observation period.  Following 
all three application routes, slightly reduced motor activity and the horizontal positioning of 
the tail was observed in all animals treated with the highest i.v. dose. There was a slight 
ptosis (eyelids down ¼) in a few animals in all i.v. treatment groups. Slight cyanosis and 
general vasoconstriction was noted in one male treated with the highest i.v. dose, and one 
male treated with the medium i.v. dose. Slightly slower motor activity of all treated and 
control animals was observed following the s.c. application. Also, slight muscular hypotonia 
was noted on day 3 in three males treated with the highest dose and one male treated with 
the lowest dose. Irregular breathing, decrease in motor activity, somnolence, ataxia, 
catalepsy and muscular hypotonia were observed in all males from the additional group 
administered i.p. with 1000 dose multiplication. A proportion of the effects noted could be 
attributed to the application of the large amount of fluid, since the constant volume was not 
respected for this group. Afterwards, the frequency and character of breathing were 
observed once a week and were found to remain within the physiological limits. 
Intensive phonation during the manipulation with animals was registered for i.v. dosed 
groups. The frequency of intensive phonation intensified between days 9 and 14 of the 
observation period, which was not noted in control animals. Statistically significant 
difference was detected for increased phonation in all treatment groups of males, IVF3 and 
IVF2, compared to controls (p  0.000001). Following the s.c. application, each phonation 
was registered, and there was no prominent difference in phonation in males, while a 
statistically significant difference in phonation was noted for group SCF3 (p = 0.000001), 
compared to the control.  
The tested combination induced no lethality and demonstrated a low level of toxicity in high 
doses. The fact that neither organ or tissue damage, nor organ mass ratio differences in 
control and experimental groups were detected indicates that the application of the tested 
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combination to the rats did not result in a permanent adverse toxicological effect on the 
examined organs. Reversible signs of toxicity disappeared with substance elimination and 
usually were not followed by a permanent tissue damage.   
High doses of met-enkephalins produce effects on OP3 () receptors in the range of sedation, 
mood changes, miosis, respiratory depression and gastrointestinal disturbances (Plotnikoff 
et al., 1997; Brunton and Parker, 2008). The evidence of ptosis, motor activity changes, 
horizontal positioning of the tail or increased phonation could suggest opioid pathway 
engagement. Increased intensity of phonation was clearly noted for all i.v. dosed treatment 
groups, but not at all in control animals (Rakanović-Todić et al, 2011).  
3.2 Subacute toxicity study 
The subacute toxicity study with the subcutaneous (s.c.) administration of Enkorten was 
conducted with three experimental groups, each of 10 Wistar albino rats (both males and 
females) and the control group of 20 Wistar albino rats (both males and females) during four 
weeks. Neither lethal outcomes nor toxic signs were observed during the study. The absence 
of pronounced toxicity of the substances was confirmed by the body weight gain in both 
experimental and control groups of animals during the study period. The ability of 
gaining or maintaining the body weight is considered to be a non-specific indicator of the 
health status of the animal (Gad and Chengelis, 1998), especially in toxicity studies with 
multiple applications. Furthermore, the average food and water consumption as well as 
the percentage ratio of stool mass were balanced between male and female groups. 
Neither external nor internal examination of animals sacrificed at the end of the study 
revealed any macroscopic pathological changes. Histopathological analysis revealed no 
microscopic pathological changes in tissue samples of liver, kidneys, lungs, heart, brain, 
spleen and thymus. All examined tissues showed a normal structure. No statistically 
significant differences in post-mortem organ weights were noted between male and 
female groups. The results of subacute toxicity study indicated that the tested 
combination of substances was not toxic when administered s.c. and repeatedly during 
four weeks (Todić et al, 2007).  
3.3 Subchronic toxicity study  
The subchronic toxicity study with intramuscular administration of Enkorten was 
conducted with three experimental groups, each of 10 Wistar albino rats (both males and 
females) and the control group of 15 Wistar albino rats (both males and females) during 
three month.  
As a part of this study, the electrocardiogram (ECG) was recorded in 6 animals from each of 
the experimental groups (3 males + 3 females) and from the control group (3 males + 3 
females), which in total amounts to 24 animals. The ECG was recorded on the day before the 
study commenced, as well as during the third, fifth, seventh, ninth and the eleventh week of 
the study and on the day before the planned sacrificing of animals. The electrocardiograph 
Schiller Resting ECG, connected to a personal computer was used for ECG registration. The 
computer program SEMA - 200 Vet (a program for ECG analysis in veterinary medicine) 
was used for the analysis of the registered curves. This program calculated the average 
values of the heart rate (FSR bits/min) and the duration of the RR interval (ms), P wave 
(ms), PQ interval (ms), QRS complex (ms) and QT interval (ms).  
www.intechopen.com
 
Rheumatoid Arthritis – Treatment 
 
164 
In the subchronic toxicity study, not a single lethal outcome was registered. No statistically 
significant differences between experimental and control groups in body weight of animals, 
in food and water consumption were documented. No statistically significant differences 
between experimental and control groups in the sensitivity to pain, frequency of breathing, 
were detected, nor differences in post-mortem organ weights during macroscopic 
examination and histopathological analysis of the tissue samples. No statistically significant 
differences were found between experimental and control groups in the average duration of 
ECG parameters and biochemical parameters in males. The results of the investigation of the 
Enkorten influence on the biochemical parameters in females showed the following 
statistically significant differences: in the values of calcium (p = 0.046) between the third and 
the first group (FG3 vs. FG1); in the values of sodium (p = 0.044) although no statistically 
significant differences were documented in the sodium values between the individual 
experimental groups and the control group; in the values of urea (p = 0.049) although no 
statistically significant differences in the urea values between the individual experimental 
groups and the control group were documented; in the values of ASAT (p = 0.020) between 
the first and the control group; in the values of cholinesterase (p = 0.036) between the first 
and the control group (FG1 vs. FGK). It may be concluded that Enkorten probably affected 
the values of ASAT and cholinesterase in females, whereas the differences in the values of 
calcium, sodium and urea were probably due to chance. The results of the haematological 
parameters showed no statistically significant differences. It can be concluded that the tested 
substance had no impact on haematological parameters. Test results of the toxic effect 
investigation suggested that the maximum tolerated dose for male and female rats 
approximately corresponds to the dose 10 times higher than the anticipated human 
therapeutic dose. Based on the estimates obtained, we can conclude that in the study 
conducted in male and female Wistar albino rats, the investigated product showed no 
subchronic toxicity when the multiple i.m. application of animal doses equivalent to the 
either anticipated human therapeutic dose, or 5 or 10 times higher dose was performed. 
During the implementation of the subchronic Enkorten toxicity study in rabbits, individual 
cases of mortality, that cannot be linked with the activity of the test substance, have been 
documented in all experimental groups. 
3.4 Chronic toxicity study 
Based upon results of the chronic toxicity study performed on rats after the subcutaneous 
administration of Enkorten (three experimental groups, each of 40 Wistar albino rats and a 
control group) during six months, it was concluded that test substance did not show any 
toxic effects. In the course of the chronic toxicity study, not one lethal outcome was 
registered. In the course of pain sensitivity testing, the tested substance did not demonstrate 
a significant analgesic effect. Moreover, it was found that the tested substance increases the 
irritability of animals in the sense that it increases the frequency of phonation. The 
histopathology laboratory reports recorded no changes with respect to the mass of single 
organs or with respect to the macroscopic and microscopic structure of organs and tissues of 
experimental animals. The difference is noted in the mass of the left adrenal in the control 
and the first group in relation to administering the combination to male rats. Impact of 
tested substances on biochemical parameters in males showed statistically significant 
difference between the first and the control groups, as well as between the second and the 
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control group in the values of phosphorous, alkaline phosphates, and urea. The difference in 
triglycerides between the first and the control group, the AST values between the second 
and third group and the first and the third group, the ALT values between the second and 
the control group were also noticed. The sifnificant difference in the values of these 
parameters for males may be coincidental, because the difference between the groups 
treated by the highest dose level and the control group was not registered. In females a 
statistically significant difference in calcium and potassium was registered between the 
treated and the control groups. The values of phosphorus and alkaline phosphatase 
significantly differed between the first and the control group, and urea value between the 
first and the control group. Triglyceride statisticaly levels of all three treated groups 
significantly differed from the control group values. Also, there was a significantly 
difference in the values of ALT between the second and the control group. These data 
suggest that tested substance affects the value of calcium, potassium and triglycerides in 
females. The value difference of other parameters can be random, because the difference 
between the groups treated with the highest dose level and the control group was not 
registered. The data on the volume and biochemical parameters of urine showed 
statistically non significant difference between control and other groups of animals. 
Statistically significant difference between the control and first group of animals was 
found only in glucose during the second measurement. Registered difference is probably 
a consequence of stress.  
Statistical analyses of the results obtained after biochemical analyses were not statistically 
significant (including both male and female groups) for the following parameters: Ca+2, K+, 
Na+, Cl-, glucose, total proteins, albumins, globulins, total bilirubin, creatinine, cholesterol, 
cholinesterase, AST, GGT.  
The tested substance has no effect on the parameters of erythrocytes, leukocytes, 
granulocytes, thrombocytes and lymphocytes. However, the tested substance has effects on 
the value of monocytes when compared to the control group, and, as far as males are 
concerned, also in the values of lymphocytes. The tested substance did not have effects on 
the volume and biochemical parameters of urea, except for the glucose report. The noted 
difference is, probably, the result of stress (Bečić et al, 2007).  
3.5 A pilot study of the reproductive toxicity in rats 
Testing was conducted at the Institute following the NTP, 2002 (NTP - National Toxicology 
Program - Good Science and Good Decisions - NIEHS, USA, 2002), in five months old, adult 
male and female laboratory Wistar albino rats (the Institute's own breeding colony).  
In the first phase, Enkorten in a doubled human therapeutic dose (2HD; ǂ-MSH 0.028 
mg/kg + met-enkephalin 0.143 mg/kg) was administered once intraperitoneally (i.p.). 
Afterwards, animals were administered a bilateral intranasal (i.n.) dose of Enkorten eight 
times higher than the human therapeutic dose (8HD) per day, within two consecutive days. 
Administration of the substance in the above doses was carried out using the methods of 
crossing and gender matching. In the second phase, the same dosing protocol but with the 
i.n. dose increased to twenty times human therapeutic dose (20HD) was administered to the 
F1 generation of male and female rats, after they reached sexual maturity. By applying the 
same protocol, the control group received a physiological solution. During the first and the 
second phase, the typical parameters of the reproductive capacity of the animals from the F0 
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and F1 generations (gestation, litter and lactation) as well as the litter of the F1 and F2 
generations (number of offspring per litter, size, weight, growth, development and 
advancement until the age of 8 weeks) were followed. At the end of the study, post mortem 
analysis was performed on the tissue and reproductive organs of young male and female 
rats from the F2 generation. 
Comparing to controls, Enkorten did not cause any changes in the first phase of testing. In 
the second phase of the study, no gestation appeared in the experimental group from the F1 
generation, whereas in the remaining four groups the reproduction process was completely 
in accordance with the control. The number of offspring per litter ranged from 8 to 12. The 
size and weight of youth as well as gender contribution were fully in compliance with the 
control group. The development, growth, advancement of youth and lactation were 
progressing normally. Development was monitored until the age of 8 weeks of life, after 
which histopathological analysis of tissues and reproductive organs was performed. Post 
mortem analyses did not reveal significant changes in any of the young animals. No signs of 
teratogenicity were documented in the two generations of young rats. 
Based on the observed results, it can be concluded that Enkorten did not significantly affect 
the process of reproduction in rats. Enkorten did not cause any teratogenic changes. 
Histopathological reports were completely normal. 
3.6 Investigation of the effect on skin 
The investigation of the effect of Enkorten on skin was conducted using the mouse ear 
model (according to: Hypersensitivity Test Methods: NTP-National Toxicology Program - 
Good Science and Good Decisions - NIEHS, USA, 2002). 
Adult BALB/c male and female mice, divided into groups of 6 animals (the Institute's own 
breeding colony) were receiving Enkorten in 2HD (ǂ-MSH 0.028 mg/kg + met-enkephalin 
0.143 mg/kg) per day, by i.p. route, during 4 days. As an irritant, croton oil (3%, in acetone) 
was applied topically, in a volume of 25 μL, once, at the fifth day of the first Enkorten 
application. By applying the dose of Enkorten in such conditions, the 
irritation/inflammation process on the mouse skin caused by croton oil was inhibited by 
35% compared to the control group that received the physiological solution. Enkorten action 
was slightly more pronounced in males during the first 24 hours.  
The doubled human therapeutic dose of Enkorten, applied topically to skin in a volume of 
25 μL, 6 hours prior to the irritant application (3% croton oil in acetone, in the volume of 25 
μL, topically), led to the inhibition of the irritation/inflammation processes by 57% to 60%, 
compared to both male and female control mice. 
It can be concluded that Enkorten administered preventively, in a dose equivalent to the 
doubled human therapeutic dose, by i.p. route, during 4 days, reduced the 
irritation/inflammation processes for about 35%. Compared to the control, this drug, 
applied once, topically, reduced irritation/inflammation processes caused on the mouse 
skin by 60%. 
4. Pharmacokinetic study 
The aim of this study was to assign the range of values of ǂ-MSH and met-enkephalin 
plasma concentrations before and after the Enkorten application and to determine 
pharmacokinetic parameters of the test preparation (Cmax, Tmax, AUC, T½).  Cmax (Maximum 
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Plasma Concentration) is the highest concentration of drug in the blood that is measured 
after a dose; Tmax (Time to Reach Cmax)  is the time at which the highest plasma drug 
concentration occurs Cmax; AUC (Area Under the Curve) is the measure of total plasma 
exposure of drug over a given time period; T½ (Half-life) is the time required for a given 
drug concentration to decrease by 50%. 
The study was carried out on a group of 14 healthy volunteers, ages from 18 to 30, males, of 
body weight and height within the standard values. 
All volunteers received subcutaneously one dose of Enkorten preparation in the presumed 
therapeutic dose for human application. No serious side-effects were observed during the 
study. The available kit is not specific for the determination of ǂ-MSH of the test 
preparation; thus, the cross-reactivity of physiologically present ǂ-MSH and ǂ-MSH 
component of the preparation was determined. Significant interindividual differences of ǂ-
MSH plasma concentration were found. Mean values were 21.31 - 47.56 pg/ml. Mean 
plasma concentration of endogenous met-enkephalin was 50.40 pg/ml. Maximum plasma 
concentration after Enkorten application, measured 5 minutes after the application, was 
1551.86 pg/ml. The plasma half-life was 15 minutes. The concentration/time curve of met-
enkephalin implies first-order kinetics (Kusturica et al, 2009). 
5. Conclusion 
Enkorten is an immunomodulatory preparation containing two components, ǂ-melanocyte 
stimulating hormone (ǂ-MSH) and methionine-enkefalin (met-enkephalin). ǂ-MSH and 
met-enkephalin are endogenous substances of the neuropeptide group. They participate in 
the homeostatic processes, maintaining the biochemical link between the brain, 
neuroendocrine system and the immune system. The mechanism of action of both peptides 
directly reclines on both mechanisms of immune response development. The effect also 
includes analgesia, antipyretic and anti-inflammatory activities. 
Pharmacodynamics of the combination shown in the studies imply great therapeutic 
possibilities. The presumed indication range of Enkorten encompasses diseases with 
inflammatory processes as the primary pathophysiological aspect (asthma, inflammatory 
bowel disease, rheumatoid arthritis, multiple sclerosis). 
Preclinical findings indicate that the tested combination was nontoxic and well tolerated in 
doses applied by i.v., s.c., i.m., and i.p. routes, and therefore have the potential for safe 
future use as a medicine.  
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